| Generations Pt Of Barboursville | |
|
3552 Us Route 60 E, Barboursville, WV 25504-1639 | |
| (304) 733-9560 | |
| (304) 733-1141 |
| Full Name | Generations Pt Of Barboursville |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 3552 Us Route 60 E, Barboursville, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609930379 | NPI | - | NPPES |
| CN7183 | Other | RAILROAD MEDICARE | |
| 1707207 | Other | WV | BLUE CROSS BLUE SHIELD |
| 3810000-212 | Medicaid | WV |
| Provider Name | Eric J Tarr |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760545446 PECOS PAC ID: 7719891613 Enrollment ID: I20031114000622 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Jennifer Beth Trimble |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1245369743 PECOS PAC ID: 3870694656 Enrollment ID: I20070724000110 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Travis W Tarr |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1497083869 PECOS PAC ID: 9537224563 Enrollment ID: I20101110000382 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Holly R Tarr |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1053649426 PECOS PAC ID: 5991992505 Enrollment ID: I20101214000779 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Mark A Gibson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1174845259 PECOS PAC ID: 0143485441 Enrollment ID: I20121210000423 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Heather L Bowles |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417328923 PECOS PAC ID: 6709180086 Enrollment ID: I20160205002274 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Caleb Brownfield |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265889190 PECOS PAC ID: 3072808856 Enrollment ID: I20160817002583 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Rebecca L Poling |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1548505076 PECOS PAC ID: 0648541961 Enrollment ID: I20170804002253 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Christina Ferguson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487030938 PECOS PAC ID: 5890066823 Enrollment ID: I20170809000741 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Jessica Dale |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1962993576 PECOS PAC ID: 5294082343 Enrollment ID: I20180813000000 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Michael Steven Hall |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932754926 PECOS PAC ID: 2961733936 Enrollment ID: I20191007001977 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Provider Name | Paige Aubrey Tarr |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366132623 PECOS PAC ID: 1557728086 Enrollment ID: I20230526002354 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Generations Pt Of Barboursville Po Box 219, Milton, WV 25541-0219 Ph: (304) 757-2500 | Generations Pt Of Barboursville 3552 Us Route 60 E, Barboursville, WV 25504-1639 Ph: (304) 733-9560 |
News Archive
Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age.
Modafinilis used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant.
Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.
Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure-a technique that could also be used to monitor a fetus's response to therapeutic drugs-using sophisticated, noninvasive medical imaging tools.
› Verified 7 days ago
Chris Lawhon, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1018 Big Bend Rd, Barboursville, WV 25504 Phone: 304-208-0131 | |
Delinda Lea Adkins, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6354 Us Route 60 E Ste 4, Barboursville, WV 25504 Phone: 304-733-1626 | |
Holly Raye Tarr, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3552 Us Route 60 E, Barboursville, WV 25504 Phone: 304-733-9560 Fax: 304-733-1141 | |
Joseph R Crowder, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 6433 Rt 60 E Ste 125, Barboursville Physical Therapy, Barboursville, WV 25504 Phone: 304-736-3094 Fax: 304-736-3149 | |
Dr. Sarah E Matics, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3552 Us Route 60 E, Barboursville, WV 25504 Phone: 304-733-9560 Fax: 304-733-1141 | |
Lacey Danielle Cyfers, PTA Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3552 Route 60 East, Barboursville, WV 25504 Phone: 304-733-9560 Fax: 304-733-1141 | |
Caleb Brownfield, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3552 Us Route 60 E, Barboursville, WV 25504 Phone: 304-733-9560 Fax: 304-733-1141 |